Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Single-institution long-term outcomes for patients receiving nonmyeloablative conditioning hematopoeitic cell transplantation for chronic lymphocytic leukemia and follicular lymphoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Heterozygous loss of Srp72 in mice is not associated with major hematological phenotypes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Addressing the room for improvement in management of acute promyelocytic leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Cytomegalovirus-specific CD8+ T-cell responses are associated with arterial blood pressure in people living with HIV

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. "Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation"

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Non-myeloablative conditioning hematopoietic cell transplantation (NMC-HCT) has improved the treatment of chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). In a cohort of 85 patients (45 with CLL and 40 with FL), we observed 5-yr overall survival (OS) and progression-free survival (PFS) of 53% and 38% in the CLL group and 81% and 76% in the FL group. In the both the CLL group and the FL group, a strong trend toward better OS and PFS was observed among patients in complete remission (CR) at HCT. Within the FL group, sixteen patients had at one or more time points in their disease history had transformed FL. In contrast to the poor survival found in patients with transformed FL in previous studies, the 5-yr OS was almost identical in patients with transformed and non-transformed FL, 83% and 78%, respectively. In conclusion, our study supports that NMC-HCT is a safe and efficacious treatment that can provide long-term survival in elderly, heavily pretreated patients with FL and CLL. Especially patients with FL, and also transformed FL, seemed to have a great benefit of NMC-HCT, and CR at the time of HCT was an important prognostic factor.
OriginalsprogEngelsk
TidsskriftEuropean Journal of Haematology
Vol/bind89
Udgave nummer2
Sider (fra-til)151-9
Antal sider9
ISSN0902-4441
DOI
StatusUdgivet - 2012

ID: 36544730